WO2024007038A3 - Compositions and methods for the treatment of intestinal inflammation - Google Patents

Compositions and methods for the treatment of intestinal inflammation Download PDF

Info

Publication number
WO2024007038A3
WO2024007038A3 PCT/US2023/069592 US2023069592W WO2024007038A3 WO 2024007038 A3 WO2024007038 A3 WO 2024007038A3 US 2023069592 W US2023069592 W US 2023069592W WO 2024007038 A3 WO2024007038 A3 WO 2024007038A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
intestinal inflammation
treatment
compositions
subject
Prior art date
Application number
PCT/US2023/069592
Other languages
French (fr)
Other versions
WO2024007038A2 (en
Inventor
Arun Sharma
Matthew BURY
Tiffany SHARMA
Muthukumar GUNASEKARAN
Sunjay Kaushal
Original Assignee
Northwestern University
Ann And Robert H. Lurie Children's Hospital Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University, Ann And Robert H. Lurie Children's Hospital Of Chicago filed Critical Northwestern University
Publication of WO2024007038A2 publication Critical patent/WO2024007038A2/en
Publication of WO2024007038A3 publication Critical patent/WO2024007038A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed herein are composition and methods for treating a subject having intestinal inflammation. The methods comprise administering an effective amount of c-Kit+ CD45-mesenchymal stem cells to a subject in need of a treatment for intestinal inflammation.
PCT/US2023/069592 2022-07-01 2023-07-03 Compositions and methods for the treatment of intestinal inflammation WO2024007038A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263367557P 2022-07-01 2022-07-01
US63/367,557 2022-07-01

Publications (2)

Publication Number Publication Date
WO2024007038A2 WO2024007038A2 (en) 2024-01-04
WO2024007038A3 true WO2024007038A3 (en) 2024-02-22

Family

ID=89381607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/069592 WO2024007038A2 (en) 2022-07-01 2023-07-03 Compositions and methods for the treatment of intestinal inflammation

Country Status (1)

Country Link
WO (1) WO2024007038A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183272A1 (en) * 2011-11-30 2013-07-18 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US20190112578A1 (en) * 2016-04-26 2019-04-18 Isletone Ab Derivation and Self-Renewal of Multipotent Cells and Uses Thereof
US20200323924A1 (en) * 2016-04-15 2020-10-15 Temple University-Of The Commonwealth System Of Higher Education Microrna-294 and lin28a as a driver of cardiac tissue proliferation in response to pathological injury
US20210187038A1 (en) * 2014-05-14 2021-06-24 University Of Maryland, Baltimore Cardiac stem cells for cardiac repair

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130183272A1 (en) * 2011-11-30 2013-07-18 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
US20210187038A1 (en) * 2014-05-14 2021-06-24 University Of Maryland, Baltimore Cardiac stem cells for cardiac repair
US20200323924A1 (en) * 2016-04-15 2020-10-15 Temple University-Of The Commonwealth System Of Higher Education Microrna-294 and lin28a as a driver of cardiac tissue proliferation in response to pathological injury
US20190112578A1 (en) * 2016-04-26 2019-04-18 Isletone Ab Derivation and Self-Renewal of Multipotent Cells and Uses Thereof

Also Published As

Publication number Publication date
WO2024007038A2 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
JOP20220179A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
MX2021008751A (en) Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders.
KR20160067311A (en) A pharmaceutical composition comprising extracts of sterculia lychophora for preventing, improving or treating disease of oral cavity
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
WO2023081830A3 (en) Compositions and treatments with nirogacestat
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
WO2024007038A3 (en) Compositions and methods for the treatment of intestinal inflammation
MX2023007080A (en) Method for treating fibrosis.
EP2575456A4 (en) Compositions and methods for treating bruises
Balasubramaniam et al. Emerging technologies and potential applications of algae in dentistry–A critical review
CN103784336A (en) Toothpaste containing bovine lactoferrin
WO2023038968A3 (en) Compositions and methods to treat skin disorders
WO2012059874A1 (en) A mouthwash composition for managing oral mucositis, process and methods thereof
Sharma et al. Placentrex gel used as a surgical wound healing agent: a case report
CA2064478A1 (en) Ophthalmic composition
WO2022187682A3 (en) Stroma-free nk cell differentiation from human pluripotent stem cells
CN109106643B (en) Skin care composition with acne removing and anti-aging effects and preparation method of mask
Megala et al. Effect of Pithecellobium dulce (Roxb.) Benth. fruit extract on cysteamine induced duodenal ulcer in rats
WO2024006292A3 (en) Methods of treating cancer
RU2712246C1 (en) Method of treating human arthritis
RU2623061C1 (en) Means for skin diseases treatment have anti-inflammatory, wound-healing, antibacterial, anti-viral, anti-fungal action
WO2023245092A3 (en) STRESS EDITING OF CAMKIIδ
AU2024900656A0 (en) Compositions and methods for the treatment of dermal disease
Kanlıöz et al. Symptomatic efficacy of aloe vera 2% cream in the treatment of chronic anal fissure
CA3240074A1 (en) Inhibitors of menin-mll interaction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23832667

Country of ref document: EP

Kind code of ref document: A2